EBS

Emergent BioSolutions Inc. - 10-Q Summary (Period Ended Sept 30, 2010)

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Emergent BioSolutions Inc. for the period ended September 30, 2010. The company operates in two segments: Biodefense (focused on the FDA-approved anthrax vaccine BioThrax) and Commercial (vaccines and therapies for infectious diseases). The company is an accelerated filer incorporated in Delaware. As of October 29, 2010, there were 34,720,191 shares of common stock outstanding.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. Debt consists of $12.04 million current portion and $36.23 million long-term portion.

Material Changes vs. Prior Period

• Revenue: For the nine months ended Sept 30, 2010, total revenue increased slightly to $182.9 million from $181.0 million in the prior year. This was driven by a 91% increase in contracts and grants revenue ($20.9 million vs. $11.0 million), partially offset by a 5% decrease in product sales ($162.0 million vs. $170.0 million) due to fewer BioThrax doses delivered and the absence of a one-time 2009 payment related to expiry dating approval.
• Profitability: Net income attributable to Emergent decreased slightly to $25.5 million from $26.9 million year-over-year. Operating income increased to $38.6 million from $36.0 million.
• Cost Structure: Cost of product sales decreased 13% to $30.1 million due to improved production yields. Research and development expenses increased 8% to $59.7 million, driven by biodefense programs and technology platform development.
• Liquidity: Cash and cash equivalents increased significantly to $151.2 million from $102.9 million at year-end 2009, driven by strong operating cash flow ($75.4 million) and the collection of receivables.

Guidance, Outlook, Risks, and Unusual Items

• Acquisition of Trubion: On October 28, 2010 (subsequent to the period end), the company completed the acquisition of Trubion Pharmaceuticals, Inc. for approximately $27.9 million in cash and stock. This adds oncology and autoimmunity product candidates to the pipeline.
• Government Contracts: The company relies heavily on U.S. government contracts for BioThrax. A significant contract with BARDA for large-scale manufacturing in Building 55 (Lansing, MI) was awarded in July 2010, valued at up to $107 million over five years.
• Unusual Items: The company recorded a $1.0 million charge in "Other income (expense)" related to the settlement of a loan with Protein Sciences Corporation (PSC). The PSC litigation was settled in November 2010 for $11.5 million (principal plus interest).
• Legal Proceedings: Class-action lawsuits regarding the Trubion acquisition were filed in August 2010. An agreement in principle to settle these actions was reached in October 2010, with potential attorney fees up to $475,000 to be paid by Trubion.
• Risks: Key risks include dependence on U.S. government funding, the complexity of manufacturing biologics, regulatory approval uncertainties (including the "animal rule"), and the integration of the Trubion acquisition.

Investor Verification Checklist

• BioThrax Demand: Verify the timing and volume of future U.S. government orders for BioThrax, as this drives the majority of revenue.
• Trubion Integration: Assess the financial impact and development timeline of the newly acquired Trubion product candidates (SBI-087, TRU-016) and associated contingent value rights (CVRs).
• Building 55 Status: Confirm the progress of qualification and validation for the new large-scale manufacturing facility in Lansing, Michigan, which is critical for future capacity.
• Debt Covenants: Review the terms of the $48.3 million outstanding debt, particularly regarding balloon payments and covenants that could restrict future financing.
• Regulatory Approvals: Monitor FDA progress on label expansions for BioThrax and regulatory pathways for the commercial pipeline (TB, Typhoid, Influenza vaccines).